Guanylate-binding protein 1 (GBP1) might be a prognostic biomarker in lung adenocarcinoma, according to a study published in the Journal of Clinical Laboratory Analysis.
In this study, researchers retrospectively analyzed clinical data of 221 lung adenocarcinoma patients. Subsequently, patients’ tumor tissue specimens were collated and paired with adjacent tissue specimens for GBP1 detection via immunohistochemistry assay.
According to the results, GBP1 expression was upregulated in tumor tissues juxtaposed to adjacent tissues (P<0.001). Moreover, high tumor GBP1 expression was associated with larger tumor size (P=0.030), positive lymph node metastasis (P=0.001), advanced TNM stage (P=0.001), and abnormal preoperative carcinoembryonic antigen level (P=0.026). Furthermore, the researchers noted that tumor GBP1 high expression was associated with reduced disease-free survival (DFS) and overall survival (OS) and was of independent value in predicting worse DFS and OS.
The researchers concluded, “GBP1 correlates with advanced tumor features and worse survival profiles, suggesting its value to be a prognostic biomarker in management of lung adenocarcinoma.”